Albireo to Present at Upcoming Investor Conferences
BOSTON — March 28, 2017 — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor conferences in April:
1st Annual H.C. Wainwright & Company NASH Investor Conference
Location: St. Regis New York in New York City (Versailles Room)
Presentation date / time: Monday, April 3, 2017, at 11:00 a.m. ET
Presenter: Paresh N. Soni, MD, PhD, Chief Medical Officer
16th Annual Needham Healthcare Conference
Location: Westin Grand Central Hotel in New York City
Presentation date / time: Tuesday, April 4, 2017, at 3:00 p.m. ET
Presenter: Ron Cooper, President and Chief Executive Officer.
A live audio webcast of the Needham conference presentation will be accessible from the Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
LifeSci Advisors, LLC.
Source: Albireo Pharma, Inc.